Investigating biochemical and molecular factors in soft tissue sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze normal and sarcoma cells by utilizing human tissue samples obtained from patients undergoing procedures to remove tissue. The research will focus on identifying specific biochemical, proteomic, epigenetic, and molecular genetic markers that can predict clinical outcomes and responsiveness to therapy in soft tissue sarcoma. Blood samples will also be collected to measure biochemical factors that may aid in understanding the behavior of sarcoma. The study will utilize leftover tissue from diagnostic or therapeutic procedures, ensuring minimal additional burden on participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes.
* Patients will be entered without preference for any particular racial/ethnic group or gender.
* Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy.
* Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube

Exclusion Criteria:

\- None

Where it's running

• Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Consent and Followup)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Consent and Follow up)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack (Consent and Follow-Up)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Consent and Followup)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Singer Singer, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Samuel Singer, MD
• Phone: 212-639-2940

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Fluorescence-guided surgery to reduce unexpected positive margins in high-grade sarcoma

  This phase II trial tests whether adding fluorescence-guided surgery with indocyanine green can lower unexpected positive margins in patients with high-grade sarcoma compared to standard surgery.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07650656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.